Home
Kun Tuo

Kun Tuo Market Share Analysis for June 2026

kun tuo, as a full-service contract research organization (cro) specially set up in china market and is a wholly owned by iqvia, is dedicated to provide high-quality and reliable cost effective research services for drug and medical device & diagnostic (mdd) research and development in china.

Industry: N/A

Domainkuntuo.cn

Year Founded2011

Employees501 - 1000

Annual Revenue$5M - $10M

Kun Tuo

Kun Tuo (including company regionals)

kuntuo.cn

See more website traffic and engagement information

Kun Tuo Revenue up to June 2026 is 5M - 10M

revenue generated by Kun Tuo top domains

Kun Tuo top domains revenue over 3 years

Revenue for Kun Tuo top domains

kuntuo.cn5M - 10M

See more with Sales Intelligence

Total visits to Kun Tuo's top domains

Understand Kun Tuo market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Kun Tuo's top domains

Analyze Kun Tuo engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Kun Tuo's top domains

See how Kun Tuo keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Kun Tuo top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Kun Tuo

These are the website technologies, by industry, used by Kun Tuo top domains

Content Management System (3)

WordPress

Conversion & Analytics (2)

Google Analytics

Audio Video Media (1)

Brightcove

Email Services (1)

Microsoft Exchange Online

More Technologies

4

See all

News & Signals from Kun Tuo

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDark Horse Consulting Inc. partners with Kuntuo.Dark Horse Consulting Group and KunTuo announce Memorandum of Understanding providing cell and gene therapy developers with an accelerated path to clinical development in China.